Profund Advisors LLC Has $249,000 Stake in Syndax Pharmaceuticals, Inc. $SNDX

Profund Advisors LLC reduced its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 24.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,639 shares of the company’s stock after selling 8,842 shares during the quarter. Profund Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $249,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quarry LP acquired a new position in shares of Syndax Pharmaceuticals during the 1st quarter worth about $25,000. Magnetar Financial LLC bought a new position in Syndax Pharmaceuticals during the first quarter worth about $132,000. Corton Capital Inc. acquired a new position in Syndax Pharmaceuticals during the second quarter worth approximately $167,000. Fox Run Management L.L.C. bought a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $172,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at approximately $179,000.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 157,307 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the transaction, the chief executive officer owned 298,661 shares in the company, valued at $4,901,027.01. This trade represents a 34.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dennis Podlesak sold 19,200 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.84, for a total value of $304,128.00. Following the sale, the director owned 191,763 shares of the company’s stock, valued at approximately $3,037,525.92. The trade was a 9.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.10% of the stock is currently owned by insiders.

Syndax Pharmaceuticals Trading Down 0.2%

Shares of Syndax Pharmaceuticals stock opened at $16.62 on Friday. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. The firm has a 50-day moving average of $15.28 and a 200-day moving average of $12.78. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $18.00. The stock has a market cap of $1.44 billion, a PE ratio of -4.27 and a beta of 0.73.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.04. The business had revenue of $45.87 million during the quarter, compared to analysts’ expectations of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business’s revenue was up 266.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.98) EPS. As a group, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SNDX shares. B. Riley raised Syndax Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 6th. UBS Group upped their price objective on shares of Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Stifel Nicolaus started coverage on shares of Syndax Pharmaceuticals in a research note on Wednesday, September 10th. They set a “buy” rating and a $44.00 target price for the company. Barclays upped their price target on shares of Syndax Pharmaceuticals from $19.00 to $22.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $35.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).